Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Raw Materials (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Raw Materials for 9 consecutive years, with $59.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Raw Materials rose 200.26% year-over-year to $59.2 million, compared with a TTM value of $59.2 million through Dec 2025, up 200.26%, and an annual FY2025 reading of $59.2 million, up 200.26% over the prior year.
  • Raw Materials was $59.2 million for Q4 2025 at Heron Therapeutics, up from $32.8 million in the prior quarter.
  • Across five years, Raw Materials topped out at $59.2 million in Q4 2025 and bottomed at $15.1 million in Q4 2022.
  • Average Raw Materials over 5 years is $22.9 million, with a median of $20.2 million recorded in 2021.
  • The sharpest move saw Raw Materials plummeted 36.02% in 2023, then skyrocketed 200.26% in 2025.
  • Year by year, Raw Materials stood at $21.2 million in 2021, then decreased by 28.58% to $15.1 million in 2022, then grew by 16.56% to $17.6 million in 2023, then grew by 11.85% to $19.7 million in 2024, then surged by 200.26% to $59.2 million in 2025.
  • Business Quant data shows Raw Materials for HRTX at $59.2 million in Q4 2025, $32.8 million in Q3 2025, and $35.8 million in Q2 2025.